Skip to content

Released Feb 28, 2022, after the close

10-K filed Feb 28, 2022, 59 days after period end · 0000950170-22-002312

Q4 2021 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$10.65Mderived+28.7% vs Q4 2020+25.1% vs Q3 2021
Net Income-$38.13MderivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$35,036,000N/M
Operating Cash Flowderived-$21,580,000N/M
Margins · derived
Operating margin-328.9%−28.7 pt vs Q4 2020
Net margin-357.8%+361.5 pt vs Q4 2020

What the release said

The release

Same quarter

MetricQ4 2021derived from reported figuresQ4 2020Q4 2019Q4 2018
Revenue$10.65M$8.28M$11.31M$19.09M
Net Income-$38.13M-$59.54M-$14.79M-$1.49M
EPS Diluted—-$1.48-$0.65-$0.07

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR